James R. Mansfield
Welcome to my web site. The focus of my work over the last two decades or so has been on the application of spectroscopic and imaging methods to medicine. This has involved projects as wide ranging as the diagnosis of cancer by mid-infrared spectroscopy or the early diagnosis of rheumatoid arthritis using near-infrared spectroscopy, to several hyperspectral (or spectral or multispectral, depending on which nomenclature you prefer) imaging applications, from preclinical in vivo imaging to digital pathology and microscopy. I have great deal of experience in the application of a range of imaging methods to biomedical research, drug development and clinical research.
Currently I am the Director of Tissue Applications at PerkinElmer, Inc (Nasdaq: PKI) working on digital pathology and tissue microscopy imaging and analysis methods and applications. This covers all of the former CRi products (Nuance, Trio, inForm and Vectra) as well as the digital pathology systems from 3DHistech. In addition to being the product line’s “chief evangelist” and travelling all over the world visiting laboratories to talk to them about what we do, my research right now involves imaging and analysis methods to phenotype and count immune cells in situ in tissue sections. This is somewhat analogous to how flow cytometry can phenotype cells using multiple markers, but is done in an imaging mode in FFPE tissues and is sometimes called “tissue cytometry.” Here is a nice example of per-cell multi-marker quantitation and tissue cytometry in lung cancer.
I worked for 8 years as the Product Manager, MSI Systems, and Senior Spectral Imaging Scientist at Cambridge Research & Instrumentation (CRi, www.cri-inc.com), prior to its acquisition by Caliper Life Sciences, and then PerkinElmer, where I worked on product development and management of their line of multispectral imaging systems. Two of these products are for microscopic applications (Nuance and Vectra) and the other is for small animal imaging (Maestro), which received an R&D 100 Award in 2005.
Before starting at CRI, I was working at a small company called Hypermed, which I had helped to co-found. Hypermed was formed to do research into and commercialize many of the skin oxygenation and tissue hydration applications of hyperspectral imaging that we have developed. While at Hypermed, I also did some work for Lumen Laboratories developing a time-resolved fluorescence confocal macro-imaging system and some data analysis methods to look at some intercalating dye and DNA systems.
I worked as the Director of Analysis at Argose, Inc. for three years. Argose is a medical device company developing a noninvasive glucose-monitoring device that uses a proprietary skin autofluorescence methodology. There I managed a group of 8 scientists and mathematicians working on a methodology for making clinically useful non-invasive glucose measurements.
Before that, I worked at the Institute for Biodiagnostics, a part of the National Research Council of Canada, where I first began using spectroscopic methods for medical applications. During my 8 years at the NRC, our group was focusing on developing medical diagnostic methods using spectroscopy. I was working in three major areas: development of a hyperspectral imaging system and its applications in medicine; non-invasive diagnosis and monitoring of disease (rheumatoid arthritis and basal cell carcinoma); and non-subjective classification of ex-vivo cancer spectra.
In general, pretty much all of the projects on which I have worked have involved some form of optical spectroscopy (mid-infrared, near infrared, visible, Raman and fluorescence), in either imaging or non-imaging modes, and the application of multivariate statistical methods (aka chemometrics) to the analysis of the spectra and images.
Created by Jim Mansfield. Last Update: January 13, 2013
All rights reserved.